Showing results (81-90 of 217) with videos related to

Sort By:
Pageof 22
Journal of Obesity|August 12, 2010
Body weight control by a high-carbohydrate/low-fat diet slows the progression of diabetic kidney damage in an obese, hypertensive, type 2 diabetic rat modelShuichi Ohtomo, Yuko Izuhara, Masaomi Nangaku, et al.
American Journal of Physiology. Renal Physiology|June 16, 2005
Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicityTetsuhiro Tanaka, Ichiro Kojima, Takamoto Ohse, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|June 19, 2009
A sartan derivative with a very low angiotensin II receptor affinity ameliorates ischemic cerebral damageShunya Takizawa, Takashi Dan, Tsuyoshi Uesugi, et al.
Journal of the American Society of Nephrology : JASN|April 7, 2006
High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathwayPisut Katavetin, Toshio Miyata, Reiko Inagi, et al.
American Journal of Physiology. Renal Physiology|February 13, 2009
Glyoxalase I overexpression ameliorates renal ischemia-reperfusion injury in ratsTakanori Kumagai, Masaomi Nangaku, Ichiro Kojima, et al.
Kidney International|July 12, 2002
Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluidReiko Inagi, Toshio Miyata, Yasuhiko Ueda, et al.
Biochemical and Biophysical Research Communications|December 25, 2007
Albumin suppresses vascular endothelial growth factor via alteration of hypoxia-inducible factor/hypoxia-responsive element pathwayPisut Katavetin, Reiko Inagi, Toshio Miyata, et al.
Journal of the American Society of Nephrology : JASN|April 22, 2004
Evidence of tubular hypoxia in the early phase in the remnant kidney modelKrissanapong Manotham, Tetsuhiro Tanaka, Makiko Matsumoto, et al.
Cancer Medicine|September 24, 2022
Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitorNaoto Takahashi, Yoshihiro Kameoka, Makoto Onizuka, et al.
The Journal of Clinical Endocrinology and Metabolism|November 27, 2013
Lower serum endogenous secretory receptor for advanced glycation end product level as a risk factor of metabolic syndrome among Japanese adult men: a 2-year longitudinal studyHaruki Momma, Kaijun Niu, Yoritoshi Kobayashi, et al.
Pageof 22